1. Scrip
  2. >>Business

Decoding The Immune System To Speed Vaccine/Immunotherapy R&D

 
• By Donna Young

The Human Vaccines Project, a consortium of biopharmaceutical companies, academic institutions and nonprofit product developers, is aiming to conduct numerous small, focused trials in an effort to decode the human immune system to improve the way vaccines and immunotherapies are developed.

Vaccines have been able to eradicate smallpox, nearly eliminate polio and keep untold numbers of children free from measles, mumps and tetanus.

But vaccines against HIV, tuberculosis, malaria and cancers have eluded success, and when new fast-spreading infectious diseases emerge, like Ebola...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Business

Second Quarter M&A Activity Looks Like More Of The Same, Mostly

 
• By Joseph Haas

The biopharma sector booked nearly the same number of acquisitions in each of the past two quarters, according to Evaluate data, but there are some encouraging signs in Q2.

How Teva Is Expanding Innovation To Fuel ‘Pivot To Growth’

 
• By Jessica Merrill

Teva VP-global R&D and chief medical officer Eric Hughes talked to Scrip about building the company’s innovative pipeline in its growth-acceleration phase.

Will AstraZeneca Reach Summit And Be A PD-1xVEGF Player?

 
• By Kevin Grogan

Rumor mill suggests a $15bn licensing deal for ivonescimab is in the offing.

Eolo Pharma Advances In Obesity With Thermogenesis Approach

 
• By Aakash Babu

Emerging Company Profile: Early-stage biotech Eolo will seek cash and deals for its novel obesity drug SANA after positive Phase I results for weight loss, lean muscle mass preservation and fat mass reduction.

More from Scrip